Steer your business to success. Insights Today delivers trusted, actionable business news under 80 words on markets, leadership, and industry trends. Gain expert insights to inform your strategies and stay ahead of the curve.
Square Pharmaceuticals Ltd recorded a profit of Tk 1,465 crore in the July-March period of the current financial year, up around 9% year-on-year. The company’s Earnings Per Share (EPS) grew to Tk 18.24 from Tk 16.82 in the same period last year. Despite economic slowdown and higher operational costs, the pharmaceutical giant maintained healthy growth in revenue and profits, although EPS growth was modest due to not passing on cost increases to consumers. Photo: Square Pharmaceuticals PLC
During Elon Musk’s visit to China, Tesla received a key security clearance for its locally produced models, meeting the country’s data security requirements for smart cars. This clears a regulatory hurdle for Tesla to offer its “Full Self Driving” (FSD) features in China. Musk also reportedly partnered with Baidu for maps and navigation, inching closer to FSD approval. However, analysts suggest that the additional cost of FSD on top of Tesla’s retail prices may prove challenging for Chinese consumers.